Scientific Program

*Subject to changes
WEDNESDAY MAY 23RD, 2018

13:00-15:00  Registration, gathering and light lunch

15:00  Room Check in

15:00-17:00  Liver Forum: Case presentations and discussion
Moderator: Dr. Yoav Luria

15:00-15:30  כשהכבד פוגש את הכליה
יאנה דוידוף

15:30-16:00  ייעקב מאור

16:00-16:30  קצמן הלנה

16:00-16:30  קצמן הלנה

16:30-16:45  יוסף פרנץ ויואב לוריה

17:00-17:30:  Coffee Break and visit at the Medical Exhibition

17:30 -17:40  Welcome greetings, Prof. Eli Zuckerman, Chair, IsASL

17:40-19:48  SESSION 1:
Drug-Induced Liver Injury (DILI) and Liver Fibrosis
Chairs: Dr. Ehud Zigmond, Dr. Ohad Etzion

17:40-17:52  Immunotherapy-induced hepatitis: clinicopathological characterization in a series of four cases.
Afif Yaacob, Ella Veitzman, Tarek Saadi
Liver Unit, Rambam Health Care Campus, Israel

17:52-18:04  Epigallocatechin 3-Gallate ameliorates lipid and liver injury profile through activation of NK cells in mice model of cholestatic liver fibrosis
Johnny Amer, Ahmad Salhab, Rifaat Safadi
Liver Unit, Hadassah Ein – Kerem, Jerusalem, Israel
Macrophage-derived COMMD10 plays important protective role in the resolution of acetaminophen-induced liver injury
Keren Cohen1,2, Odelia Mouhadeb1,2, Shani Ben Shlomo1, Nathan Gluck1, Chen V arol1,2
1The research center for digestive tract and liver diseases, Sourasky medical center, Israel
2Department of clinical microbiology and immunology, Sackler faculty of medicine, Tel-Aviv University, Israel

Update from EASL: DILI Guidelines 2018
Prof. Oren Shibolet, Director, Gastroenterology Unit, Tel- Aviv Medical Center, Israel

Liver injury induced by immune checkpoint inhibitors is patient’s oriented and is associated with different histological findings
Yana Davidov1,2, Oranit Cohen-Ezra1,2, Ella Veitsman1,2, Maria Lihter1, Itai Kalisky1,2, Ziv Ben-Ari1,2
1Liver Diseases Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
2Sackler School of Medicine, Tel Aviv University, Israel

The direct effect of the citric acid cycle on hepatic stellate cell activation and on the development of liver fibrosis
Mikele Spielberg1,2, Arie Ziv Ben-Ari1,2, Rola Masoud1,2, Eirin Tzshelitzki1,2, Hadass Ma’odeh1,2
1Israel, הושמר, שיבא-המרכז הרפואי, המחלות הכבדים
2ישראל, אביב-האוניברסיטה, סאקלר

Sodium taurocholate co-transporting polypeptide (NTCP) as novel checkpoint in NK cells activity in Liver fibrosis
Johnny Amer, Ahmad Salhab, Rifaat Safadi
Liver Unit, Hadassah Ein – Kerem, Jerusalem, Israel
Leukemia inhibitory factor induces cholangiocyte proliferation and corrects the impaired bile duct morphogenesis in sortilin-deficient mice following cholestatic liver injury
Einav Hubel-Manor1, roy Avraham1, Elise G Lavoie2, Jonathan A Dranoff2, Isabel Zvibel1, Oren Shibolet1
1 The Research Center for Digestive Tract and Liver Diseases, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Israel
2 Division of Gastroenterology & Hepatology, University of Arkansas for Medical Sciences, USA

The Effectiveness of Measuring Thiopurines Metabolites in Adult Patients with Autoimmune Hepatitis
Tarek Saadi, Worood Yassin, Rimma Kramsky, Afif Yaacob, Vered Ben-Hakoon, Ella Veitzman, Hisham Sholy
Liver Unit, Rambam Health Care Campus, Israel

THURSDAY MAY 24TH, 2018

08:15-10:35 SESSION 2:
Liver Cancer and transplantation
Chairs: Dr. Yoram Menachem, Dr. Izhar Levi

08:15-08:27 Hepatitis C virus leaves an epigenetic signature following cure of infection by direct-acting antivirals
Meital Gal-Tanami, Medicine, BIU, Israel

08:27-09:02 Genetic signature of HCC: clinical applications
Prof. Jessica Zucman, France

09:02-09:14 Hypophosphatemia as an early postoperative indicator of decreased major complications rate after liver resection for colorectal liver metastases
Yael Berger1, Eviatar Nesher1, Riad Haddad1, Shlomit Tamir2, Natalia Goldberg2, David Aranovich1, Daniel Benchimol1, Hanoch Kashtan1, Eran Sadot1
1 Surgical Unit, Beilinson Hospital, Israel
2 Radiology, Beilinson Hospital, Israel
09:14-09:26  Fecal microbiota profiles as a diagnostic biomarker in cirrhosis and hepatocellular carcinoma and the impact of lifestyle and nutrition
Lapidot L1,4, Amir A, Nosenko R5, Gayshis B2, Likhter M2, Ben-Ami D2, Harony O2, Engel T2, Kalisky I2, Weiss P2, Veitsman E2, Cohen-Ezra O2, Davidov Y2, Segev S3, Koren O5, Safran M1,2, Ben-Ari Z1,2,4.
1Liver Research Laboratory, 2Liver Diseases Center, 3Medical Screening Unit, Chaim Sheba Medical Center – Tel Hashomer 4The Sackler School of Medicine, Tel Aviv University, Tel Aviv, 5Faculty of Medicine, Bar-Ilan University, Safed

09:26-09:38  Are Patients Treated with Direct Antiviral Agents for HCV Infection at Greater Risk for Extrahepatic Malignancies?
Tarek Saadi, Rimma Kramsky, Afif Yaacob, Hisham Sholy, Faheem Shehadeh, Vered Ben-Hakoon, Ella Veitzman, Jihad Khoury
Liver Unit, Rambam Health Care Campus, Israel

09:38-09:50  Prevalence and outcomes of a second extrahepatic malignancy among patients with Hepatocellular Carcinoma in an Israeli cohort
Yoram Menachem, Oren Shibolet, Hadar Maringer
Liver Unit, Sourasky Medical Center, Ichilov Hospital, Tel Aviv, Israel

09:50-10:02  Resection versus transplant listing for hepatocellular carcinoma in Israel: an intention to treat analysis
Guy Meyero vich1,3, Ido Nachmany1,3, Yaacov Goykhman1, Richard Nakache1,3, Oren Shibolet2,3, Yoram Menachem2, Helena Katsman2, Rafael Bruck2, Nir Lubezky1,3
From the department of surgery¹ and the institute of Gastroenterology², Tel Aviv Medical Center, Sackler School of Medicine³, The Nicholas and Elizabeth Cathedra of Experimental Surgery, Tel Aviv University, Israel

10:04-10:34  Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit.
Prof. Umberto Cillo, Padova, Italy
Sponsored by Novartis

10:34-10:55  Coffee Break and visit at the Medical Exhibition
10:55-12:15  **SESSION 3:**
**HCC and liver transplantation II (continued)**
**Chairs: Dr. Rawi Hazan, Dr. Marius Braun**

10:55-11:15  Resection of HCC in cirrhotics  
Dr. Riad Haddad, Carmel Medical Center

11:15-11:40  Case presentation (HCC in cirrhotic patient and discussion: Presenter TBA Discussion: Down staging, loco-regional treatment, transplantation, anti viral treatment  
Panel: Prof. Daniel Azoulay, Prof. Eythan Mor and Prof. Umberto Cillo

Eylon Lahat1, Jabar Ahmad1, Ziv Ben Ari3, Gil Golan4, Mordechi Gutman1, Daniel Azoulay1,2  
1Surgery B and hepatobiliary and pancreatic surgery, Tel Hashomer hospital, Israel  
2hepatobiliary pancreatic and liver transplantation, Henri Mondor hospital, France  
3Center of liver disease, Tel Hashomer hospital, Israel  
4Invasive Radiology, Tel Hashomer hospital, Israel

11:55-12:15  Living related donor liver transplantation: The Israeli Experience  
Prof. Eythan Mor, Rabin Medical Center

12:15-12:45  **SESSION 4:**  
**State of the art lecture**  
**Chairs: Dr. Alice Hershkovitz, Dr. Yona Kitay**

12:15-12:45  Spatial transcriptomics of the mammalian liver  
Dr. Shalev Itzkovitz, Department of molecular cell biology, Weizmann Institute

12:45-13:45  Lunch
13:45-16:20  **SESSION 5:**  
**Cirrhosis and Liver Fibrosis I**  
**Chairs: Prof. Rifaat Safadi, Dr. Matthias Karlebach**

13:45-14:05  Surgery in patients with chronic liver disease  
Prof. Adrian Reuben

14:05-14:17  Acute hemodynamic response to I.V propranolol during hepatic hemodynamic study in 26 cirrhotic patients with portal hypertension and nonbleeding esophageal varices. Correlation with esophageal bleeding and survival.  
Eyal Ashkenazi, Yulia Kovalev, Alex Haimovich, Eli Zuckerman  
Liver Unit, Carmel Medical Center, Haifa, Israel

14:17-14:29  Prevalence of minimal hepatic encephalopathy in the patients with fatty liver disease: a pilot study  
Nir Bar, Shira Deri, Jenny Rutenburg, Oren Shibolet, Helena Katchman  
Gastroenterology department, Tel Aviv Sourasky Medical Center, Israel

14:30-14:42  Liver Cirrhosis, changing of the etiology  
Naim Abu-Freha1, Najwan Kial2, Muhammad Abu Tailakh3, Ali Elsana4, Alexander Fich1, Heba Abu Kaf1, Ohad Etzion1  
1. The Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, the Arab Medical Association in the Negev, Beer-Sheva, Israel  
2. Internal Medicine Ward C, Soroka University Medical Center, Beer-Sheva, Israel  
3. Nursing Research Unit, Soroka University Medical Center  
4. Internal Medicine Ward A, Soroka University Medical Center, Beer-Sheva, Israel

14:45-15:10  Placement of TIPS prior to surgery in patients with portal hypertension.  
Prof. Daniel Azoulay
15:10-15:22  The Role of Eosinophils in CCl4 induced Liver Fibrosis
Itay Moshkovits
Itay Moshkovitz, Ayelet Kaminitz, Debby Reuveni, Chen Varol, Chen Varol, Oren Shibolet, Ehud Zigmond
Tel-Aviv Sourasky Medical Center; The Research Center for Digestive Tract & Liver Diseases, Israel

15:22-15:44  Endoscopic Ultrasound-Guided Angio-Therapy for Gastric Varices: A Single Center Experience
יולה'יברלד ג',ערן ישראלי,אריאל בנסון,סאלח דאהר,מוחמד מסארוה,ורי שְפִיד,אפשטיין
המרכז הרפואי האוניברסיטאי הדסה,המכון לגסטרואנטרולוגיה ומחלות כבד

15:45-15:57  Idiopathic non-cirrhotic portal hypertension: clinical and hemodynamic characteristics and outcome of a large cohort of patients
Eyal Ashkenazi1, Yulia Kovalev1, Alex Haimovich1, Assaf Issaschar2, Michal Naftaly-Cohen2, Marius Braun2, Rifaat Safadi3, Saleh Daher3, Daniel Shouval3, Yona Kitay-Cohen4, Ruthy Hadary4, Rawi Hazzan5, Oren Shibolet6, Michal Karmiel7, Eli Zuckerman1
1 Liver unit, Carmel Medical Center, Haifa, Israel
2 Liver Institute, Rabin Medical Center, Petah Tikva, Israel
3 Liver Unit, Institute of Gastroenterology and Liver Diseases, Hadassah Medical Center, Jerusalem, Israel
4 Liver Unit, Meir Medical Center, Israel
5 Liver Unit, HaEmek Medical Center, Afula, Israel
6 Liver Unit, Tel Aviv Medical Center, Israel
7 Liver Unit, Galilee Medical Center, Nahariya, Israel

16:00-16:20  Management of non-tumoral PVT in in candidates to liver transplantation
Prof. Daniel Azoulay

16:20-16:40  Coffee Break and visit the Exhibit Hall
16:40-17:10 The Journey of Sofosbuvir: from a molecule to a drug
Dr. Michael Mertens, Director of Hepatitis Medical Affairs, Gilead EMEA

17:10-17:22 Treatment of hepatitis C among HIV HCV coinfected patients in a real world setting – on the path to HCV elimination in a single center.
Ella Veitsman1, Tarek Saadi1,3, Afif Yacoub1, Rimma Kramsky1, Vered Ben-Hakoon1, Yaacov Baruch1,3, Margalit Lorber2,3, Jamal Hassoun2, Einat Kedem2, Eduardo Shahar2,3
1 Center for Liver Diseases, Rambam Health Care Campus, Israel
2 Institute of Immunology, Allergy and AIDS, Rambam Health Care Campus, Israel
3 Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel

17:25-17:55 Update from EASL 2018, HCV guidelines 2018
Prof. Eli Zuckerman

17:55-18:05 HCV elimination Program in Israel: to where we are going?
Mr. Julio Borman, Hetz- Israeli Patients’ organization

18:05-18:17 Awake the dormant: barriers to access to care and cure in patients with chronic HCV infection.
Orly Azulay, Eyal Ashkenazi, Yulia Kovalev, Eli Zuckerman
Liver Unit, Carmel Medical Center, Technion, Faculty of Medicine, Haifa, Israel
SESSION 7:
Viral Hepatitis II
Sponsored by Abbvie
Chairs: Dr. Seif Abu- Much, Dr Asaf Issachar

18:20-18:45 Emerging Therapies for hepatitis B: What is expected in the near future? Prof. Ran Tur-Kaspa

18:45-18:57 Real life experience with direct acting antiviral agents in patients with chronic hepatitis C and inherited bleeding disorders Yana Davidov1,2, Oranit Cohen-Ezra1,2, Ella Veitsman1, Avishag Hassid1, Dana Silverberg1, Adi Halle-Bikovski1, Keren Tzaraf1, Ziv Ben-Ari1,2 1Liver Diseases Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel 2Sackler School of Medicine, Tel Aviv University, Israel

18:57-19:09 Circulation of hepatitis E in Israel: high prevalence in pigs, Dromedary camels and in specific human populations Rachel Shirazi1, Shaul Pozzi2, Ravit Bassal3, Dan David2, Marina Wax1, Itay Bar-Or1, Efrat Asulin1, Yaniv Lustig1, Eli Schwartz4,5, Hazzan Rawai6, Ella Mendelson1,5, Ziv Ben-Ari5,7, Orna Mor1,5 1Central Virology Laboratory, Ministry of Health, Israel 2Veterinary services, Agriculture Ministry, Israel 3Israel Center for Disease Control, Ministry of Health, Israel 4Tropical Diseases, Sheba Medical Center, Israel 5Sackler Faculty of Medicine, Tel Aviv University, Israel 6Liver unit, Haemek Medical Center, Israel 7Liver unit, Sheba Medical Center, Israel

19:09-19:21 Liver steatosis predicts mortality and cancer in patients with chronic hepatitis B infection and is inversely correlated with viral replication Noam Peleg1, Assaf Issachar1,2,3, Michal Cohen-Naftaly2,3, Orly Sneh-Arhib2,3, Marius Brown2,3, Amir Shlomai1,2,3 1Internal medicine D, Rabin Medical Center, Israel 2Institute of Liver Disease, Rabin Medical Center, Israel 3Sackler Faculty of Medicine, Tel Aviv University, Israel
High frequency of multiclass HCV resistance to second-generation direct-acting antiviral failure in Israel real-life: tailored therapies are advocated

Ziv Ben-ari 1,3, Yael Gozlan 2, Rachel Shirazi 2, Aviya Rakovsky 2, Yana Davidov 1, Ella Veitsman 4, Tarek Saad 4, Marius Braun 3,5, Michal Cohen-Naftaly 3,5, Amir Shlomai 3,5, Oren Shibolet 3,6, Ehud Zigmond 3,6, Helena Katchman 3,6, Yoram Menachem 3,6, Rifaat Safadi 7, Eitan Galun 7, Eli Zuckerman 8, Assy Nimer 9, Rawi Hazzan 10, Yaakov Maor 11, Sayaf Abu-Moch 12, Ohad Etsion 13, Yoav Lurie 14, Orna Mor 2,3

1 Liver unit, Sheba Medical Center, Israel
2 Central Virology Laboratory, Ministry of Health, Israel
3 Sackler Faculty of Medicine, Tel Aviv University, Israel
4 Liver unit, Rambam Medical Center, Israel
5 Liver unit, Rabin Medical Center, Israel
6 Department of Gastroenterology, Tel-Aviv Medical Center, Israel
7 Liver unit, Hadassah Medical Center, Israel
8 Liver unit, Carmel Medical Center, Israel
9 Internal Medicine department, Galilee Medical Center, Israel
10 Liver unit, Haemek Medical Center, Israel
11 Division of Gastroenterology, Kaplan Medical Center, Israel
12 Liver unit, Hillel Yafe Medical Center, Israel
13 Liver unit, Soroka Medical Center, Israel
14 Liver unit, Shaare Zedek Medical Center, Israel

08:00-09:30 PARALLEL SESSION FOR NURSES
Coral Hall

08:00-09:30 Sponsored by NEOPHARM

08:00-08:45 PBC - אלי צוקרמן

08:45-09:30 CASE STUDY
- קריס, אחות אחותית מומן ברפואת כבד, עם סמי סינים, של תינוק, אחות אחותית, מומן ברפואת כבד של צארף, מרפאות"ז, האוניברסיטה העברית, תל אביב.
**FRIDAY MAY 25TH, 2018**

**08:15-10:12 SESSION 8:**

**Non-Alcoholic Fatty Liver Disease**

**Chairs: Prof. Oren Shibolet, Dr. Ohad Etzion**

**08:15-08:27**

Portal Lymphadenopathy Predicts Steatohepatitis and Advanced Fibrosis in Non-alcoholic Fatty Liver Disease

רפעת טאופיק ח, רון אורן, מוחמד מסארוה, מירה נאסר, סאלח דאהר

1 ספדי

המרכז הרפائي האוניברסיטאי, המinsula לגסטרואנטרולוגיה, בודדות כבד, המרכז הרפアイי אוניברסיטאי

2 הדסה, ישראל

3 מדעоторיה של הסמסטריה העברית וסמסטריה, האוניברסיטה העברית, ישראל

**08:27-08:39**

Serum sRAGE levels are associated with lifestyle and with non-alcoholic fatty liver disease

Dana Ivancovsky1,2, Shira Zelber Sagi1,2, Naomi Fliss Isakov2, Muriel Webb2,3, Oren Shibolet2,3, Revital Kariv2,3

1School of Public Health, University of Haifa, שרה

2Department of Gastroenterology, Tel-Aviv Medical Center, שרה

3The Sackler Faculty of Medicine, Tel-Aviv University, שרה

**08:39-08:51**

Reduced PI3K pathway in NK cells of F4-NAFLD patients inhibited mTOR expressions and was correlated with their impaired function

Johnny Amer, Ahmad Salhab, Sarit Doron, Rifaat Safadi

Liver Unit, Hadassah Ein Kerem Hospital, Israel

**08:51-09:04**

Quantification of Hepatic Fat – Ultrasound, Biomarkers and MR Spectroscopy

Yaakov Maor1, Na’aama Reshef2, Assaf Tal3, Hila Knobler2

1Institute of Gastroenterology and Hepatology, Kaplan Medical Center, ישראל

2The Diabetes and Metabolic Unit, Kaplan Medical Center, ישראל

3Department of Chemistry, The Weizmann Institute, ישראל
Noninvasive scoring systems predict long-term morbidity, mortality and cancer in patients with nonalcoholic fatty liver disease

Prof. Ziv Ben-Ari

Update from EASL: NASH and emerging therapies

Prof. Ziv Ben-Ari

Screening Diabetic Patients for Non-alcoholic Fatty Liver Disease (NAFLD) - Is it Cost-Effective?

Yaakov Maor1, Shira Zelber-Sagi2,3, Moshe Leshno4

1Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Israel
2Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Israel
3School of Public Health, University of Haifa, Israel
4Coller School of Management, Tel Aviv University, Israel

The pattern of elevated liver function tests in non-alcoholic fatty liver disease predicts fibrosis stage and metabolic-associated comorbidities

Dor Shirin1, Noam Peleg1,2, Orly Sneh-Aribib2, Michal Cohen-Naftaly 2, Marius Braun 2,3, Assaf Issachar 1,2 and Amir Shlomai 1,2,3*

1 Department of Medicine D, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel
2 The Liver Institute, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel
3 The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

NAFLD fibrosis score predicts diabetic complications in patients with NAFLD

Noam Peleg1, Assaf Issachar2,3, Sneh-Aribib Orly2,3, Michal Cohen-Naftaly2,3, Marius Brown2,3, Amir Shlomai2,3

1Internal medicine D, Rabin Medical Center, Israel
2Institute of Liver Disease, Rabin Medical Center, Israel
3Sackler Faculty of Medicine, Tel Aviv University, Israel
10:22-10:40  Coffee Break

10:40-10:45  Awards for outstanding clinical study, basic science study & poster

10:45  **SESSION 9:**

**Cirrhosis and Liver fibrosis II**

**Chairs: Dr. Tarek Saadi, Dr. Ella Weitzman**

10:45-11:05  Kidney injury in patients with cirrhosis
Prof. Adrian Reuben

11:05-11:17  Hepatocyte-secreted exosomes can inhibit and reverse hepatic stellate cells stimulation
Safran Michal1, Masoud Rola1, Sultan Maya1, Tachlyt ski Irena1, Balint-Lahat Nora2, Pappo Orit2, Ben-Ari Ziv1,3
1 Liver Diseases Center, 2 Pathology department Chaim Sheba Medical Center, 3 Sackler School of Medicine, Tel Aviv University, Tel Aviv

11:17-11:29  COMMD10 is important for Kupffer cell elimination of Staphylococcus aureus
Chen Varol, Shani Ben Shlomo, Odelia Mouhadeb, Nathan Gluck
The Research Center for Digestive Tract & Liver Diseases, Sourasky Medical Center and Tel Aviv University, Israel

11:30-11:42  Liver Cirrhosis, Etiology and Clinical Characteristics Disparities among minority population
Muhammad Abu Tailakh2, Liat Poupko3, Najwan Kial4, Ali Elsana5, Ohad Etzion1, Heba Abu Kaf1, Alexander Fich1, David Yardni1, Anat Nevo-Shor1, Abed Abu Ganim6, Naim Abu-Freha1
1 Nursing Research Unit, Soroka University Medical Center, Epidemiology Department, Ben-Gurion University, Beer-Sheva, Israel
2 1st years student, Medical School for International Health, Ben-Gurion University, Beer-Sheva, Israel
3 Internal Medicine Ward C, Soroka University Medical Center, Beer-Sheva, Israel.
4 Internal Medicine Ward A, Soroka University Medical Center, Beer-
11:42-11:54 The anti fibrotic effect of Aramchol on rat liver fibrosis induced by TAA and in vitro on primary hepatic stellate cells. Regina Golan-Gerstl, Nickolay Koroukhov, Rawand Khweiss, Shimon Reif, Pediatrics Department, Hadassah Medical Center, Israel.

11:54-12:06 Elevated expressions of Sodium taurocholate co-transporting polypeptide (NTCP) on NK cells impaired their function and contribute to liver fibrosis. Johnny Amer, Rifaat Safadi, Ahmad Salhab, Liver Unit, Hadassah Ein Kerem Hospital, Israel.

12:06-12:25 Business Meeting

08:30-11:15 PARALLEL SESSION FOR NURSES
Coral Hall

08:30-11:15 מושב אחיות מקביל - אולם קורל

08:30-09:15 האם ישראל יוכל להפוך למדינה ללא הפטיטיס סי? פורפ' אלי צוקרמן

09:15-10:45 Принимайте лекарство! (вшие את התרופה) – מ써ר מתן החפץ (outedEventArgs). מימיה של ה- HCV – מון גל, מרכז גל, מחקרstitות עם חולים

10:45-11:15 כל אחד יוכל לנהל את מיקרואלימינציה בקוני מחלמי הפטיטיס סי – ד"ר צבי, צבי הלוי